Amikacin population pharmacokinetics in critically Ill Kuwaiti patients

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Matar, Kamal M ^a   Al Lanqawi, Yousef ^b   Abdul Malek, Kefaya ^b   Jelliffe, Roger ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b AL AMIRI HOSPITAL   (Kuwait)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTENSIVE CARE UNIT; KUWAIT; MAJOR CLINICAL STUDY; MALE; ALGORITHM; ARAB; BIOLOGICAL MODEL; CLINICAL TRIAL; CRITICAL ILLNESS; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMIKACIN; ANTI-BACTERIAL AGENTS; ARABS; CRITICAL ILLNESS; FEMALE; HUMANS; KUWAIT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84874621869     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/202818     Document Type: Article

References (19)

1. Kummana C., Yuen K., Parenteral aminoglycoside therapy. Selection, administrationandmonitoring. Drugs 1994 47 902 913 (Pubitemid 24170831)
2. Erdman S. M., Rodvold K. A., Pryka R. D., An updated comparison of drug dosing methods. Part III: aminoglycoside antibiotics. Clinical Pharmacokinetics 1991 20 5 374 388 2-s2.0-0025854724
3. Beckhouse M. J., Whyte I. M., Byth P. L., Napier J. C., Smith A. J., Altered aminoglycoside pharmacokinetics in the critically ill. Anaesthesia and Intensive Care 1988 16 4 418 422 2-s2.0-0024210968 (Pubitemid 19011281)
4. De Gatta M. D. M. F., Moreno S. R., Calvo M. V., Ardanuy R., Domínguez-Gil A., Lanao J. M., Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. Journal of Pharmacy and Pharmacology 2009 61 6 759 766 2-s2.0-68849083843 10.1211/jpp/61.06.0008
5. Roberts J. A., Lipman J., Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clinical Pharmacokinetics 2006 45 8 756 773 2-s2.0-33746784161 (Pubitemid 44182274)
6. Pea F., Viale P., Furlanut M., Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clinical Pharmacokinetics 2005 44 10 1009 1034 2-s2.0-25144470553 10.2165/00003088-200544100-00002 (Pubitemid 41356389)
7. Mehrotra R., De Gaudio R., Palazzo M., Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Medicine 2004 30 12 2145 2156 2-s2.0-12944307865 10.1007/s00134-004-2428-9 (Pubitemid 40174249)
8. Jelliffe R., Estimation of creatinine clearance in patients with unstable renal function, withoutaurinespecimen. American Journal of Nephrology 2002 22 320 324
9. Bustad A., Terziivanov D., Leary R., Port R., Schumitzky A., Jelliffe R., Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clinical Pharmacokinetics 2006 45 4 365 383 2-s2.0-33745603097 10.2165/00003088- 200645040-00003
10. Jhee S. S., Burm J. P., Gill M. A., Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods. Antimicrobial Agents and Chemotherapy 1994 38 9 2073 2077 2-s2.0-0028102171 (Pubitemid 24278803)
11. Domke I., Cremer P., Huchtemann M., Therapeutic drug monitoring on COBAS INTEGRA 400-evaluation results. Clinical Laboratory 2000 46 9-10 509 515 2-s2.0-0033804447
12. Jelliffe R. W., Schumitzky A., Bayard D., Milman M., Van Guilder M., Wang X., Jiang F., Barbaut X., Maire P., Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new "Multiple Model" dosage design, Bayesian feedback and individualised target goals. Clinical Pharmacokinetics 1998 34 1 57 77 2-s2.0-0031985373 10.2165/00003088-199834010- 00003 (Pubitemid 28041092)
13. Sheiner L. B., Beal S. L., Some suggestions for measuring predictive performance. Journal of Pharmacokinetics and Biopharmaceutics 1981 9 4 503 512 2-s2.0-0019604592 10.1007/BF01060893
14. Zaske D. E., Strate R. G., Kohls P. R., Amikacin pharmacokinetics: wide interpatient variation in 98 patients. Journal of Clinical Pharmacology 1991 31 2 158 163 2-s2.0-0025965286
15. Gauthier T., Lacarelle B., Marre F., Villard P. H., Catalin J., Durand A., Predictive performance of two software packages (USCPACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients. International Journal of Bio-Medical Computing 1994 36 1-2 131 134 2-s2.0-0028233865 10.1016/0020-7101(94)90104-X (Pubitemid 24173890)
16. Lugo G., Castaňeda-Hernândez G., Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis. Ther Drug Monit 1997 19 271 276 (Pubitemid 28053480)
17. Debord J., Pessis C., Voultoury J. C., Marquet P., Lotfi H., Merle L., Lachatre G., Population pharmacokinetics of amikacin in intensive care unit patients studied by NPEM algorithm. Fundamental and Clinical Pharmacology 1995 9 1 57 61 2-s2.0-0028842037
18. Debord J., Voultoury J., Lachâtre G., Gay C., Favereau J., Gay R., Population pharmacokinetic paramters for Bayesian monitoring of amikacintherapy in intensive care unit patients. European Journal of Clinical Pharmacology 1992 43 435 436
19. Bertsekas D., Dynamic Programming: Deterministic and Stochastic Models 1987 Englewood Cliffs, NJ, USA Prentice-Hall